While the rest of the medical device world zigzags through incremental improvements and corporate tap dancing, Kardium’s been quietly engineering a mic drop. Their Globe® Pulsed Field System is a single-catheter beast, 122 electrodes, zero compromises. It maps and ablates atrial fibrillation (AF) in one shot, with real-time feedback so precise it could make a Swiss watch blush. For patients with paroxysmal AF or persistent AF, 59 million globally, the Globe® system doesn’t just promise efficiency, it delivers freedom. And in this game, freedom from arrhythmia is everything.
On July 2, Kardium locked in a fresh $250 million in equity financing, led by Janus Henderson Investors, Qatar Investment Authority (QIA), MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital. Major props to returning believers T. Rowe Price Associates, T. Rowe Price Investment Management, and Durable Capital Partners LP, because when you’ve seen a market-making machine up close, you don’t just invest, you double down. Oh, and there’s also an undisclosed strategic backer in the mix. No name, no problem, just know the smart money knows where to park.
Kevin Chaplin (CEO) and Doug Goertzen (President & Co-founder) have kept the squad focused. That includes Amos Michelson (Chairman & Co-founder), Dan Gelbart (Advisor & Co-founder), and Dr. Sam Lichtenstein (Advisor & Co-founder), a blend of industrial design, surgical brilliance, and straight-up startup nerve. Together, they’ve built Kardium into a 340-person powerhouse in Burnaby, BC, with clinical legs stretching into Europe and the U.S. CE mark? Secured. FDA clearance? On deck. Commercial launch? Coming in hot later this year.
And this isn’t vaporware wrapped in buzzwords. The PULSAR IDE trial showed 84.2% freedom from arrhythmia at 12 months for paroxysmal AF, 80% for persistent. Real numbers. Real people. Real change. Add in a proprietary navigation software stack, high-def mapping, and pulsed field tech that spares surrounding tissue like a surgeon with Jedi hands, Kardium’s not just in the game, they’re tilting the board.
The $250M haul will fuel regulatory pushes, manufacturing scale-ups, and frontline hires in sales and clinical support. Because when you’re treating a condition as widespread and misunderstood as AF, you don’t go small, you go Globe®.
Tag the venture firms. Mention the founders. Tell your friends in electrophysiology: the wave’s not coming. It’s already here.
